Converting enzyme inhibitor-induced changes of plasma angiotensinogen concentration in the rat.

[1]  H. Ibsen,et al.  The renin‐angiotensin system during converting enzyme inhibition with captopril in patients with severe treatment‐resistant hypertension , 1984, European journal of clinical investigation.

[2]  J. Ménard,et al.  Influence of converting-enzyme inhibition on rat des-angiotensin I-angiotensinogen. , 1984, The American journal of physiology.

[3]  E. Schiffrin,et al.  Effect of enalapril (MK-421), an orally active angiotensin I converting enzyme inhibitor, on blood pressure, active and inactive plasma renin, urinary prostaglandin E2, and kallikrein excretion in conscious rats. , 1984, Canadian journal of physiology and pharmacology.

[4]  A. Doyle,et al.  A COMPARISON OF THE ACTIVITY OF THE ANGIOTENSIN CONVERTING ENZYME INHIBITORS SQ 14 225, SA 446, AND MK 421 , 1983, Clinical and experimental pharmacology & physiology.

[5]  H. Herrmann,et al.  The Feedback Regulation of Angiotensinogen Production by Components of the Renin‐Angiotensin System , 1983, Circulation research.

[6]  Sweet Cs.  Pharmacological properties of the converting enzyme inhibitor, enalapril maleate (MK-421). , 1983 .

[7]  J. Ménard,et al.  Direct radioimmunoassay of rat angiotensinogen and its application to rats in various endocrine states. , 1982, Clinical science.

[8]  D. Ganten,et al.  SA446, a new orally active converting enzyme inhibitor: antihypertensive action and comparison with captopril in stroke-prone spontaneously hypersensitive rats. , 1982, European journal of pharmacology.

[9]  J. Giese,et al.  Captopril combined with thiazide lowers renin substrate concentration: implications for methodology in renin assays. , 1981, Clinical science.

[10]  K. Hofbauer,et al.  No Evidence for Product Inhibition of the Renin‐Angiotensinogen Reaction in the Rat , 1977, Circulation research.

[11]  P. Seglen.  Preparation of isolated rat liver cells. , 1976, Methods in cell biology.